A Phase I Clinical Study of BBI608 Administered with Paclitaxel in Patients with Previously treated Unresectable/Recurrent Gastric Cancer

Status

Unknown

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080222370

Enrollment

Registered

2014-01-17

Start date

2014-01-17

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Unresectable/recurrent gastric cancer

Interventions

investigational material(s) Generic name etc : BBI608 INN of investigational material : napabucasin Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - Signed, written informed consent - Unresectable/recurrent gastric cancer which was histologically confirmed as an adenocarcinoma (including adenocarcinomas of the gastroesophageal junction) - Disease progression after one or more chemotherapy regimens OR recurrence within 6 months of completion of postoperative adjuvant therapy for unresectable/recurrent gastric cancer - Maintained normal organ functions - ECOG performance status of 0 or 1 etc.

Exclusion criteria

Exclusion criteria: - Patients with any known untreated brain metastases etc.

Design outcomes

Primary

Measure	Time frame
- Safety - Pharmacokinetics CTCAE (ver.4.0)	—

Secondary

Measure	Time frame
- Efficacy RECIST (ver.1.1)	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026